Zolgensma denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma as Duplicate Therapy

Zolgensma (onasemnogene abeparvovec) is a one-time gene therapy for spinal muscular atrophy (SMA). UnitedHealthcare may issue a duplicate-therapy denial when another SMA-modifying treatment — such as nusinersen or risdiplam — is already active on the patient's profile. The insurer's system flags the combination as therapeutically redundant and may refuse to authorize a second agent targeting the same underlying disease mechanism.

This denial is worth challenging. Zolgensma works through a fundamentally different mechanism than other SMA therapies: it delivers a functional copy of the SMN1 gene rather than modifying splicing or protein production. Your prescriber can make a compelling medical-necessity argument that the two treatments are not interchangeable duplicates. Additionally, clinical guidelines from relevant professional societies (including the guidance maintained by organizations such as the Child Neurology Society and SMA-specific expert panels) address sequencing and combination considerations — your neurologist can document why Zolgensma is indicated for this patient's specific situation even in the context of prior or concurrent therapy.

## Your Appeal Rights

• Internal appeal: Submit a written internal appeal within the timeframe stated in your denial letter (typically 180 days). Request a full-and-fair review under ERISA §503 if you are in an employer-sponsored plan.
• External review: If the internal appeal is denied, you are entitled to an independent external review under ACA §2719. The external review window is generally up to four months from the final internal denial. For urgent situations, request an expedited external review, which reviewers must complete within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — genetic test results confirming SMA type and SMN1/SMN2 copy number status, signed by the ordering clinician. 2. Treatment history — dates, dosing schedules, and documented clinical response (or lack thereof / plateau) for any prior or current SMA therapies. 3. Clinical severity record — motor function assessments, pulmonary function notes, and functional milestones from the chart. 4. Prescriber medical-necessity letter — your neurologist should explain why Zolgensma is not duplicative but rather serves a distinct therapeutic purpose for this patient. 5. Applicable guideline reference — cite the relevant society guidance supporting the treatment approach without paraphrasing specific numbers.

## Criteria-Mapping Structure

Pull the full text of UnitedHealthcare's current published coverage policy for Zolgensma and the FDA-approved prescribing information. For each criterion listed:

| Policy Requirement | Chart Evidence | |---|---| | Confirmed SMA diagnosis with genetic documentation | [Lab report date and result] | | Age / weight / disease stage eligibility per label | [Chart entry with date] | | Prior therapy history and clinical rationale for Zolgensma | [Treatment log + prescriber note] | | Absence of contraindications per prescribing label | [Prescriber attestation] |

Answer every criterion with a specific dated chart entry. A point-by-point response that demonstrates your patient's case meets each published requirement — and that Zolgensma addresses a mechanism no existing therapy covers — gives the reviewer a clear path to overturn the denial.